Iovance Biotherapeutics, Inc. (IOVA)

Market Cap	1.59B +49.2%
Revenue (ttm)	263.50M +60.6%
Net Income	-390.98M
EPS	-1.09
Shares Out	411.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,684,185
Open	3.930
Previous Close	3.800
Day's Range	3.850 - 3.970
52-Week Range	1.639 - 5.630
Beta	0.76
Analysts	Buy
Price Target	9.00 (+133.16%)
Earnings Date	May 7, 2026

About IOVA

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 975
• Stock Exchange: NASDAQ
• Ticker Symbol: IOVA
• Website: https://www.iovance.com

Financial Performance

In 2025, Iovance Biotherapeutics's revenue was $263.50 million, an increase of 60.60% compared to the previous year's $164.07 million. Losses were -$390.98 million, 5.05% more than in 2024.

Analyst Summary

According to 10 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price target is $9.0, which is an increase of 133.16% from the latest price.

Price Target

$9.0

(133.16% upside)

Analyst Consensus: Buy